A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 20 Mar 2018 Planned End Date changed from 12 Feb 2020 to 5 May 2020.
- 20 Mar 2018 Planned primary completion date changed from 16 Jul 2019 to 29 Oct 2019.
- 08 Feb 2018 Status changed from not yet recruiting to recruiting, according to a Regeneron Pharmaceuticals media release.